PMID- 36430275
OWN - NLM
STAT- MEDLINE
DCOM- 20221129
LR  - 20221213
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 22
DP  - 2022 Nov 9
TI  - PAC(1), VPAC(1), and VPAC(2) Receptor Expression in Rat and Human Trigeminal 
      Ganglia: Characterization of PACAP-Responsive Receptor Antibodies.
LID - 10.3390/ijms232213797 [doi]
LID - 13797
AB  - Pituitary adenylate cyclase-activating peptide (PACAP) is a neuropeptide 
      expressed in the trigeminal ganglia (TG). The TG conducts nociceptive signals in 
      the head and may play roles in migraine. PACAP infusion provokes headaches in 
      healthy individuals and migraine-like attacks in patients; however, it is not 
      clear whether targeting this system could be therapeutically efficacious. To 
      effectively target the PACAP system, an understanding of PACAP receptor 
      distribution is required. Therefore, this study aimed to characterize 
      commercially available antibodies and use these to detect PACAP-responsive 
      receptors in the TG. Antibodies were initially validated in receptor transfected 
      cell models and then used to explore receptor expression in rat and human TG. 
      Antibodies were identified that could detect PACAP-responsive receptors, 
      including the first antibody to differentiate between the PAC(1n) and PAC(1s) 
      receptor splice variants. PAC(1), VPAC(1), and VPAC(2) receptor-like 
      immunoreactivity were observed in subpopulations of both neuronal and glial-like 
      cells in the TG. In this study, PAC(1), VPAC(1), and VPAC(2) receptors were 
      detected in the TG, suggesting they are all potential targets to treat migraine. 
      These antibodies may be useful tools to help elucidate PACAP-responsive receptor 
      expression in tissues. However, most antibodies exhibited limitations, requiring 
      the use of multiple methodologies and the careful inclusion of controls.
FAU - Tasma, Zoe
AU  - Tasma Z
AUID- ORCID: 0000-0002-7652-6004
AD  - School of Biological Sciences, The University of Auckland, Auckland 1010, New 
      Zealand.
FAU - Siow, Andrew
AU  - Siow A
AUID- ORCID: 0000-0002-0341-065X
AD  - School of Biological Sciences, The University of Auckland, Auckland 1010, New 
      Zealand.
AD  - School of Chemical Sciences, The University of Auckland, Auckland 1010, New 
      Zealand.
FAU - Harris, Paul W R
AU  - Harris PWR
AD  - School of Biological Sciences, The University of Auckland, Auckland 1010, New 
      Zealand.
AD  - School of Chemical Sciences, The University of Auckland, Auckland 1010, New 
      Zealand.
AD  - Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, 
      Auckland 1010, New Zealand.
FAU - Brimble, Margaret A
AU  - Brimble MA
AUID- ORCID: 0000-0002-7086-4096
AD  - School of Biological Sciences, The University of Auckland, Auckland 1010, New 
      Zealand.
AD  - School of Chemical Sciences, The University of Auckland, Auckland 1010, New 
      Zealand.
AD  - Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, 
      Auckland 1010, New Zealand.
FAU - O'Carroll, Simon J
AU  - O'Carroll SJ
AUID- ORCID: 0000-0003-1628-4864
AD  - Department of Anatomy and Medical Imaging, and Centre for Brain Research, Faculty 
      of Medical and Health Science, The University of Auckland, Auckland 1023, New 
      Zealand.
FAU - Hay, Debbie L
AU  - Hay DL
AUID- ORCID: 0000-0002-9558-5122
AD  - Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, 
      Auckland 1010, New Zealand.
AD  - Department of Pharmacology and Toxicology, The University of Otago, Dunedin 9016, 
      New Zealand.
FAU - Walker, Christopher S
AU  - Walker CS
AUID- ORCID: 0000-0001-8151-4123
AD  - School of Biological Sciences, The University of Auckland, Auckland 1010, New 
      Zealand.
AD  - Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, 
      Auckland 1010, New Zealand.
LA  - eng
GR  - N/A/Royal Society of New Zealand/
GR  - N/A/Health Research Council, New Zealand/
PT  - Journal Article
DEP - 20221109
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide)
RN  - 0 (Pituitary Adenylate Cyclase-Activating Polypeptide)
RN  - 0 (Antibodies)
SB  - IM
MH  - Humans
MH  - Rats
MH  - Animals
MH  - Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/genetics/metabolism
MH  - *Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism
MH  - Trigeminal Ganglion/metabolism
MH  - Gene Expression
MH  - Antibodies
MH  - *Migraine Disorders/genetics
PMC - PMC9697343
OTO - NOTNLM
OT  - PAC1 receptor
OT  - PACAP
OT  - VIP
OT  - VPAC1 receptor
OT  - VPAC2 receptor
OT  - migraine
OT  - trigeminal ganglia
COIS- Debbie L. Hay is or has been a consultant or speaker for Lilly, Amgen, Teva, 
      Intarcia, Merck Sharp & Dohme and has received research funding from Living Cell 
      Technologies (Sydney, Australia) and Abbvie Inc. (Mettawa, IL USA.) in the past 
      three years. Christopher S. Walker has received research support from Living Cell 
      Technologies and Abbvie Inc.
EDAT- 2022/11/27 06:00
MHDA- 2022/11/30 06:00
PMCR- 2022/11/09
CRDT- 2022/11/26 01:15
PHST- 2022/09/29 00:00 [received]
PHST- 2022/11/02 00:00 [revised]
PHST- 2022/11/06 00:00 [accepted]
PHST- 2022/11/26 01:15 [entrez]
PHST- 2022/11/27 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/11/09 00:00 [pmc-release]
AID - ijms232213797 [pii]
AID - ijms-23-13797 [pii]
AID - 10.3390/ijms232213797 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Nov 9;23(22):13797. doi: 10.3390/ijms232213797.